Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : Merck to Present at the 32nd Annual J.P. Morgan Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/10/2014 | 02:01pm CET

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, Merck's chairman and chief executive officer, is scheduled to present at the 32ndAnnual J.P. Morgan Healthcare Conference in San Francisco on January 13 at 4:00 p.m. PST (7:00 p.m. EST). Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/events-and-presentations/home.html.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2012 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Merck
Media Contact:
Kelley Dougherty, 908-423-4291
or
Investor Contact:
Carol Ferguson, 908-423-4465


© Business Wire 2014
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
01:14p MERCK : European Medicines Agency’s CHMP Recommends Approval of Merck&rsqu..
03/23 MERCK : Findings from Merck & Company in the Area of Pharmaceutical Science Repo..
03/23 MERCK : New Human Papillomavirus Findings from Merck & Company Reported (Develop..
03/23 MERCK : New Hypoglycemia Study Findings Have Been Reported by Investigators at M..
03/23 MERCK : StayWell Earns Re-accreditation From the National Committee for Quality ..
03/22 MERCK ANIMAL HEALTH : Completes Acquisition of Vallée S.A.
03/17 MERCK : Keytruda`s head-to-head against Opdivo rockets meds to Nos. 2 and 3 in a..
03/16 MERCK & CO., INC. (NYSE : MRK) Sued By Numerous Plaintiffs Over Harm Caused By I..
03/14 MERCK : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pedia..
03/14 MERCK : Provides Update on Supplemental Biologics License Application (sBLA) for..
More news
Sector news : Pharmaceuticals - NEC
03:42p NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03:14a YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/23 Pharma Development Budgets Grow As Roche Remains A Believer
03/23 Gilead Doesn't Offer A Compelling Risk/Reward
03/22 Merck loses appeal in Fosamax failure-to-warn suit; shares ease 1%
03/22 BIOLINERX : Update And Preview Of The Company's Q4 And FY 2016 Financial Results..
03/22 SNIPPET ROUNDUP : Medica And Cell Medica Are In The Money, But Endo And Valeant ..
Advertisement
Financials ($)
Sales 2017 39 720 M
EBIT 2017 13 557 M
Net income 2017 8 404 M
Debt 2017 4 038 M
Yield 2017 2,97%
P/E ratio 2017 19,66
P/E ratio 2018 16,33
EV / Sales 2017 4,48x
EV / Sales 2018 4,33x
Capitalization 173 740 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,0 $
Spread / Average Target 9,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.7.49%173 740
JOHNSON & JOHNSON9.28%341 301
ROCHE HOLDING LTD.7.52%219 164
PFIZER INC.5.57%204 201
NOVARTIS AG-0.94%196 550
SANOFI7.63%115 841
More Results